The latanoprost monotherapy survey in New Zealand, 2000.
A State subsidy for latanoprost has been recently introduced. It is subject to several conditions including that it should only be used as monotherapy. A prospective survey of all New Zealand ophthalmologists was undertaken to determine the outcome of the widespread trial of latanoprost monotherapy. The return rate was 82%. Of 2900 patients on latanoprost nation-wide, 14.7% were monotherapy failures. Of these, 93% were due to inadequate intraocular pressure control but this subgroup had adequate control on two or more medications in 88%. Ophthalmologists had 635 patients that were not trialed as monotherapy, of which 565 (89%) were due to a perceived risk. In those patients treated with latanoprost, 85% were adequately controlled as monotherapy.